Journal Article

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

Jiang, Y, Hou, J, Zheng, C, Lu, Y, Bi, E, Wang, Q, Yi, Q, Zheng, Y, Wang, S, Li, R, Qian, J

2018

Overview

Our previous studies showed that macrophages (MФs), especially myeloma-associated MФs (MAMs), induce chemoresistance in human myeloma. Here we explored the potential of targeting MФs, by using colony-stimulating factor 1 receptor (CSF1R)-blocking mAbs, to treat myeloma. Our results showed that CSF1R blockade specifically inhibited the differentiation, proliferation and survival of murine M2 MФs and MAMs, and repolarized MAMs towards M1-like MФs in vitro. CSF1R blockade alone inhibited myeloma growth in vivo, by partially depleting MAMs, polarizing MAMs to the M1 phenotype, and inducing a tumor-specific cytotoxic CD4+ T-cell response. Similarly, genetically depleting MФs in myeloma-bearing MMDTR mice retarded myeloma growth in vivo. Furthermore, the combination of CSF1R blockade and chemotherapy such as bortezomib or melphalan displayed an additive therapeutic efficacy against established myeloma. Finally, a fully human CSF1R blocking mAb, similar to its murine counterpart, was able to inhibit the differentiation, proliferation and survival of human MФs. Thus, this study provides the first direct in vivo evidence that MΦs and MAMs are indeed important for myeloma development and progression. Our results also suggest that targeting MAMs by CSF1R blocking mAbs may be promising methods to (re)sensitize myeloma cells to chemotherapy and promote anti-myeloma immune responses in patients.

• Publisher: Nature Publishing Group
• Subject: Antibodies / Blocking antibodies / Bortezomib / CD4 antigen / Chemoresistance / Chemotherapy / Colony-stimulating factor / Cytotoxicity / Differentiation / Immune response / In vivo methods and tests / Lymphocytes T / Macrophage colony-stimulating factor / Macrophages / Melphalan / Monoclonal antibodies / Multiple myeloma / Survival / T cell receptors